Targeted protein degradation (TPD) approaches, including molecular glue degraders (MGDs) and proteolysis targeting chimeras (PROTACs), can overcome traditional occupancy-based inhibitor...
Continue Reading
Strategies to stimulate dendritic cell (DC) activity, such as ex vivo generation and priming of DC vaccines, have been explored...
Continue Reading
KRAS mutations act as primary initiators of carcinogenesis in several major cancers and are present in approximately 20 – 25%...
Continue Reading
From hematologic malignancies to solid tumors Introduction: Amid a surge of advancements in immunotherapy, T cell engager (TCE) therapy has...
Continue Reading
Antibody-targeted therapies—including antibody-drug conjugates (ADCs), antibody-oligonucleotide conjugates (AOCs), and degrader-antibody conjugates (DACs)—are reshaping precision medicine by enabling highly selective delivery...
Continue Reading
Overview of AAV Gene Therapy: Evolution and Current Landscape Adeno-associated virus (AAV) is a non-enveloped, replication-defective single-stranded DNA virus belonging...
Continue Reading
Evidence suggests that type 2 diabetes mellitus (T2DM) is associated with cognitive dysfunction and an increased risk of developing neurocognitive...
Continue Reading
T-cell engagers (TCEs) are a class of bispecific antibodies that simultaneously bind tumor cells and T cells, activating T cells...
Continue Reading
Mechanisms, Recent Progress, and Animal Models Radionuclide drug conjugates (RDCs), a novel class of precision tumor-targeting therapeutic and diagnostic agents,...
Continue Reading
